How much is NeuroGen Pharma worth in 2026?

NeuroGen Pharma has a current valuation of N/A based on their Buyout/LBO round and secondary market data.

How much funding has NeuroGen Pharma raised?

NeuroGen Pharma has raised N/A in total funding across 1 funding rounds.

NeuroGen Pharma

Buildings and Property

NeuroGen Pharma valuation and funding history | Last updated: November 30, 2024 | 1 funding rounds

Current Valuation

N/A

As of November 30, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

Buyout/LBO

$680.0M

Last Funding

Nov 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
November 30, 2024	Buyout/LBO	$680.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

NeuroGen Pharma is currently valued at N/A as of November 30, 2024.

Track NeuroGen Pharma Valuation Updates

Get notified when NeuroGen Pharma raises new funding or valuation changes

Explore More Data

Detailed analysis for NeuroGen Pharma

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock NeuroGen Pharma's valuation history, funding rounds, and growth metrics.

No credit card required

What is NeuroGen Pharma Worth in 2026?

NeuroGen Pharma is a leading private company in the Buildings and Property sector. Track NeuroGen Pharma's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How NeuroGen Pharma Valuation is Determined

Private company valuations like NeuroGen Pharma's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.